The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 271/07 - 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A robot connector, including: a connector configured to connect to a mounting surface of a robot; a guiding insert that is compressible, wherein the guiding insert has an opening configured to receive a guide tube; a guide tube holder with an opening wherein the guide tube is attached to the connector and the opening is configured to receive the compressible guiding insert; and a locking mechanism configured to lock the guiding insert and the guide tube to the connector.
Variations of integral navigation controls may be used in conjunction with a medical instrument to provide navigation functions for an image guided surgery (IGS) system that is in communication with the integral navigation controls. In some variations, a medical instrument with integrated navigation wheels allows movement of a cursor of the IGS system along the x and y axis by scrolling the wheel, or allows selection, zooming, or other controls by combined clicking and/or scrolling of wheels, and may be sterilized or discarded along with the device. In some other variations, a control overlay may be temporarily attached to the medical instrument to provide additional controls, such as buttons or a pointing stick, and then removed and sterilized or discarded after a procedure. In each variation, inputs may be communicated via wire or wirelessly to an IGS system to provide navigation of images during a surgical procedure.
A61B 17/24 - Surgical instruments, devices or methods, e.g. tourniquets for use in the oral cavity, larynx, bronchial passages or nose; Tongue scrapers
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A system, includes (i) a processor, which is configured to receive, in a zone between first and second regions of an organ of a patient, one or more signals, at least a signal among the signals includes first and second components indicative of an electrophysiological (EP) property of the organ, and based on a relation between the first and second components, the processor is configured to estimate a location of at least a transition zone between the first and second regions, and (ii) a display, configured to display at least the estimated transition zone over a map of the organ.
Described embodiments include apparatus that includes a catheter and a tip electrode, at a distal end of the catheter, shaped to define a plurality of microelectrode apertures. The apparatus further includes at least one printed circuit board (PCB) disposed within a lumen of the catheter, and a plurality of microelectrodes coupled to the PCB and at least partly situated within the microelectrode apertures, the PCB being configured to carry signals from the microelectrodes. Other embodiments are also described.
The disclosure encompasses systems, compositions, and methods for use in vivo, including for reinforcement of soft tissue in an individual. The systems, compositions, and methods may utilize three-dimensionally printed scaffolds comprising at least a polymer scaffold and an extracellular matrix component(s), including comprised on the scaffold. The polymer scaffold may comprise particular unit cell structures of a specific design and patterns of alternating configurations of the unit cell structures.
A method includes obtaining an electroanatomical map, which maps a portion of a heart while the heart experiences an arrhythmia, obtaining a sequence of images of the heart acquired by an ultrasonic probe, the sequence including one or more arrhythmic images acquired while the heart experiences the arrhythmia and one or more rhythmic images acquired while the heart is in sinus rhythm, the ultrasonic probe including a sensor that outputs, during the acquisition of the sequence of images, a signal indicating a location and an orientation of the probe in a coordinate system of the electroanatomical map, based on the signal, identifying, in one of the arrhythmic images, an anatomical portion represented by a particular portion of the electroanatomical map, by tracking the anatomical portion through the sequence of images, identifying the anatomical portion in at least one of the rhythmic images, and displaying an output in response thereto.
The present invention relates to improved contact lens packages and methods of use and manufacture/assembly. A contact lens package may include a first cavity that houses a contact lens and packaging solution, and a second cavity that houses an absorbent member. In one aspect, the first cavity and the second cavity may be in fluid isolation from one another when the package is in an unopened state.
The present invention relates to a method of treating agitation in a human patient with dementia, comprising administering to the human patient with dementia in need thereof a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof to treat agitation, wherein R1-R4 are defined herein:
The present invention relates to a method of treating agitation in a human patient with dementia, comprising administering to the human patient with dementia in need thereof a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof to treat agitation, wherein R1-R4 are defined herein:
The present invention relates to a method of treating agitation in a human patient with dementia, comprising administering to the human patient with dementia in need thereof a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof to treat agitation, wherein R1-R4 are defined herein:
wherein the human patient has at least an about 20% reduction in their symptom of agitation, relative to the patient prior to administration of the compound of formula (I).
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
11.
Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors
The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I)
The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I)
The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I)
wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 9/00 - Medicinal preparations characterised by special physical form
A stabilized coronary sinus catheter system having a proximal section and a distal section with a memory shape portion, and a tip, distal of the memory shape portion. A handle having a body, a tip deflection actuator, a memory shape portion deployment actuator, and an axis. The tip is in line with the axis and the tip deflection actuator is at a first position. The tip is deflected out of alignment with the axis when the tip deflection actuator is at a second position. A third position is a delivery configuration where the memory shape portion and the tip are in line with the axis. The memory shape portion deployment actuator is at a first location. A deployed configuration allows the memory shape portion to form a predetermined shape conforming to the shape of the coronary sinus when the memory shape portion deployment actuator is at a second location.
A delivery sheath to catheter coupler includes a cylindrical shaft and a coupling member. The cylindrical shaft extends along an axis and is configured for longitudinal alignment with an insertion port of a catheter delivery sheath. The cylindrical shaft includes a proximal end, a distal end, and a lumen extending from the proximal end to the distal end along the axis. The lumen is sized to receive an end effector of a catheter. The coupling member is attached to the cylindrical shaft and is configured for selective securement to the catheter delivery sheath. The coupling member is configured to align the axis of the lumen with a longitudinal axis of the insertion port when the coupling member is selectively secured to the catheter delivery sheath.
In one general aspect, various embodiments of the present invention can include a motorized surgical cutting and fastening instrument having a drive shaft, a motor selectively engageable with the drive shaft, and a manual return mechanism configured to operably disengage the motor from the drive shaft and retract the drive shaft. In at least one embodiment, a surgeon, or other operator of the surgical instrument, can utilize the manual return mechanism to retract the drive shaft after it has been advanced, especially when the motor, or a power source supplying the motor, has failed or is otherwise unable to provide a force sufficient to retract the drive shaft.
A61B 17/10 - Surgical instruments, devices or methods, e.g. tourniquets for closing wounds, or holding wounds closed, e.g. surgical staples; Accessories for use therewith for applying or removing wound clamps; Wound clamp magazines
Embodiments of the present invention provide isolated proteins comprising antigen binding domains that bind kallikrein related peptidase 2 (hK2), including monospecific and bispecific antibodies. Additional embodiments of the invention provide polynucleotides encoding the hk2-specific proteins, vectors, host cells, and methods of making and using them.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/34 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
16.
METHOD FOR DETECTION OF ANTIBODY-DEPENDENT CELLULAR PHAGOCYTOSIS
222 atmosphere for a period of time sufficient to increase ADCP activity of the phagocytic cell; and detecting ADCP activity of the phagocytic cell in the sample. In some embodiments, the phagocytic cells are cultured in the presence of target cells.
(1) Human pharmaceutical preparations for the prevention and treatment of auto-immune diseases, cardiovascular diseases, pulmonary hypertension, pulmonary arterial hypertension, gastro-intestinal diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, cerebrovascular diseases and digital ulcers; human pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; human pharmaceutical preparations for the prevention and treatment of neurological diseases, namely Alzheimer's, Huntington's disease, multiple sclerosis, and cerebral palsy; human pharmaceutical preparations for the prevention and treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia; human pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases, psoriasis; Human pharmaceutical preparations for the prevention and treatment of hemolytic disease of the newborn; human pharmaceuticals preparations, namely anxiolytic medications, anti-virals, anti-inflammatories, anti-infectives, anti-allergic medications; human pharmaceutical preparations for the relief of pain
(1) Human pharmaceutical preparations for the prevention and treatment of auto-immune diseases, cardiovascular diseases, pulmonary hypertension, pulmonary arterial hypertension, gastro-intestinal diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, cerebrovascular diseases and digital ulcers; human pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; human pharmaceutical preparations for the prevention and treatment of neurological diseases, namely Alzheimer's, Huntington's disease, multiple sclerosis, and cerebral palsy; human pharmaceutical preparations for the prevention and treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia; human pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases, psoriasis; Human pharmaceutical preparations for the prevention and treatment of hemolytic disease of the newborn; human pharmaceuticals preparations, namely anxiolytic medications, anti-virals, anti-inflammatories, anti-infectives, anti-allergic medications; human pharmaceutical preparations for the relief of pain
(1) Human pharmaceutical preparations for the prevention and treatment of auto-immune diseases, cardiovascular diseases, pulmonary hypertension, pulmonary arterial hypertension, gastro-intestinal diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, cerebrovascular diseases and digital ulcers; human pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; human pharmaceutical preparations for the prevention and treatment of neurological diseases, namely Alzheimer's, Huntington's disease, multiple sclerosis, and cerebral palsy; human pharmaceutical preparations for the prevention and treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia; human pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases, psoriasis; Human pharmaceutical preparations for the prevention and treatment of hemolytic disease of the newborn; human pharmaceuticals preparations, namely anxiolytic medications, anti-virals, anti-inflammatories, anti-infectives, anti-allergic medications; human pharmaceutical preparations for the relief of pain
(1) Human pharmaceutical preparations for the prevention and treatment of auto-immune diseases, cardiovascular diseases, pulmonary hypertension, pulmonary arterial hypertension, gastro-intestinal diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, cerebrovascular diseases and digital ulcers; human pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; human pharmaceutical preparations for the prevention and treatment of neurological diseases, namely Alzheimer's, Huntington's disease, multiple sclerosis, and cerebral palsy; human pharmaceutical preparations for the prevention and treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia; human pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases, psoriasis; Human pharmaceutical preparations for the prevention and treatment of hemolytic disease of the newborn; human pharmaceuticals preparations, namely anxiolytic medications, anti-virals, anti-inflammatories, anti-infectives, anti-allergic medications; human pharmaceutical preparations for the relief of pain
(1) Human pharmaceutical preparations for the prevention and treatment of auto-immune diseases, cardiovascular diseases, pulmonary hypertension, pulmonary arterial hypertension, gastro-intestinal diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, cerebrovascular diseases and digital ulcers; human pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; human pharmaceutical preparations for the prevention and treatment of neurological diseases, namely Alzheimer's, Huntington's disease, multiple sclerosis, and cerebral palsy; human pharmaceutical preparations for the prevention and treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia; human pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases, psoriasis; Human pharmaceutical preparations for the prevention and treatment of hemolytic disease of the newborn; human pharmaceuticals preparations, namely anxiolytic medications, anti-virals, anti-inflammatories, anti-infectives, anti-allergic medications; human pharmaceutical preparations for the relief of pain
(1) Human pharmaceutical preparations for the prevention and treatment of auto-immune diseases, cardiovascular diseases, pulmonary hypertension, pulmonary arterial hypertension, gastro-intestinal diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, cerebrovascular diseases and digital ulcers; human pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; human pharmaceutical preparations for the prevention and treatment of neurological diseases, namely Alzheimer's, Huntington's disease, multiple sclerosis, and cerebral palsy; human pharmaceutical preparations for the prevention and treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia; human pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases, psoriasis; Human pharmaceutical preparations for the prevention and treatment of hemolytic disease of the newborn; human pharmaceuticals preparations, namely anxiolytic medications, anti-virals, anti-inflammatories, anti-infectives, anti-allergic medications; human pharmaceutical preparations for the relief of pain
(1) Human pharmaceutical preparations for the prevention and treatment of auto-immune diseases, cardiovascular diseases, pulmonary hypertension, pulmonary arterial hypertension, gastro-intestinal diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, cerebrovascular diseases and digital ulcers; human pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; human pharmaceutical preparations for the prevention and treatment of neurological diseases, namely Alzheimer's, Huntington's disease, multiple sclerosis, and cerebral palsy; human pharmaceutical preparations for the prevention and treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia; human pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases, psoriasis; Human pharmaceutical preparations for the prevention and treatment of hemolytic disease of the newborn; human pharmaceuticals preparations, namely anxiolytic medications, anti-virals, anti-inflammatories, anti-infectives, anti-allergic medications; human pharmaceutical preparations for the relief of pain
(1) Human pharmaceutical preparations for the prevention and treatment of auto-immune diseases, cardiovascular diseases, pulmonary hypertension, pulmonary arterial hypertension, gastro-intestinal diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, cerebrovascular diseases and digital ulcers; human pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; human pharmaceutical preparations for the prevention and treatment of neurological diseases, namely Alzheimer's, Huntington's disease, multiple sclerosis, and cerebral palsy; human pharmaceutical preparations for the prevention and treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, and schizophrenia; human pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases, psoriasis; Human pharmaceutical preparations for the prevention and treatment of hemolytic disease of the newborn; human pharmaceuticals preparations, namely anxiolytic medications, anti-virals, anti-inflammatories, anti-infectives, anti-allergic medications; human pharmaceutical preparations for the relief of pain
The present invention is directed to compounds of Formulas (I, IIa and IIb):
The present invention is directed to compounds of Formulas (I, IIa and IIb):
The present invention is directed to compounds of Formulas (I, IIa and IIb):
The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
An embolic implantation system configured to deliver an embolic implant intravascularly to a treatment site includes an elongated delivery tube to which the embolic implant is detachably attached by a flexible loop extending through a retaining ring or opening on the embolic implant and an elongated detachment member or pull wire extending through the delivery tube and flexible loop. The pull wire has a bump near its distal end that inhibits the pull wire from moving further distally when the bump presses distally against the flexible loop and/or retaining ring. The flexible loop and retaining ring thereby serve as a distal obstruction obstructing distal movement of the bump and thereby distal movement of the pull wire into the implant.
A61B 17/12 - Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
The objectives for the designs presented herein can be for a variably flexible catheter for vascular applications. The catheter can include a catheter shaft extending along a longitudinal axis. The catheter can include an exterior surface that includes an exterior surface area. The catheter can include a plurality of ridges each including an apex, an amplitude, a wavelength, and a trough with respect to the longitudinal axis. The apexes of the plurality of ridges can define a contact exterior surface area less than the exterior surface area. When the exterior surface of the catheter is applied to vascular tissue, contact between the vascular tissue made primarily by the contact exterior surface area.
A bunion correcting system can include a first body portion and a second body portion. One of the first and second body portions can be pivotable relative to the other of the first and second body portions. The first body portion can include a first surface, a second surface spaced from the first surface along a transverse direction, and a first aperture extending from the first surface to the second surface. The first aperture can be adapted to receive a first bone anchor to couple the first body portion to a metatarsal bone. The second body portion can include a third surface, a fourth surface spaced from the third surface along the transverse direction, and a second aperture extending from the third surface to the fourth surface. The second aperture can be adapted to receive a second bone anchor to couple the second body portion to a cuneiform bone.
Provided herein are hydrogel-hydrocolloid sealant compositions for use as soft-tissue sealants. The compositions can include a cross-linkable electrophilic component; a cross-linkable nucleophilic component; a swellable filler material including gelatin; and, a buffer having a pH in the range of about 9.0 to about 10.0. The compositions can have a first fluid state and a second crosslinked state, and in the crosslinked state, the electrophilic and nucleophilic components can crosslink to form a crosslinked hydrogel network where the swellable filler material including gelatin is disposed within the crosslinked network. Also provided are systems and methods of manufacturing the sealant compositions as well as methods of repairing soft tissue defects including applying the sealant compositions disclosed herein.
Methods of designing a hybrid clinical trial including an external control arm (ECA) study located in at least one site, to support a randomized clinical trial (RCT) study for a treatment of a condition are disclosed. A Mahalanobis distance value is calculated based on a point comprising a set of values corresponding to a first plurality of feature variables corresponding to at least one ECA candidate; and a distribution of points comprising a set of values corresponding to the first plurality of feature variables of each of a plurality of RCT participants that have received the treatment. ECA candidates may be excluded as ECA participants if they are deemed outliers based on the Mahalanobis distance value. Recruitment is dynamically adjusted into at least one ECA participant site database by comparing sets of feature variables in at least one ECA participant site database to corresponding sets of feature variables in the RCT participant database.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
31.
PHACOEMULSIFICATION PROBE STROKE LENGTH MAXIMIZATION SYSTEM
A phacoemulsification system including a phacoemulsification probe having a probe body, a horn disposed at least partially in the probe body, a needle coupled with the horn and configured to be inserted into an eye, and a piezoelectric actuator disposed in the probe body and configured to vibrate the horn and the needle in a first direction with a stroke length with respect to the probe body; a signal generator configured to generate a drive signal to drive a vibration of the piezoelectric actuator; a stroke measurement apparatus configured to provide indications of the stroke length of the needle over time; and a controller configured to dynamically adjust a frequency of the drive signal so as to maximize the stroke length and maintain mechanical resonance of the needle responsively to the provided indications of the stroke length.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
Provided herein are hydrogel-hydrocolloid sealant compositions for use as soft-tissue sealants. The compositions can include a cross-linkable electrophilic component; a cross-linkable nucleophilic component; a swellable filler material including gelatin; and, a buffer having a pH in the range of about 9.0 to about 10.0. The compositions can have a first fluid state and a second crosslinked state, and in the crosslinked state, the electrophilic and nucleophilic components can crosslink to form a crosslinked hydrogel network where the swellable filler material including gelatin is disposed within the crosslinked network. Also provided are systems and methods of manufacturing the sealant compositions as well as methods of repairing soft tissue defects including applying the sealant compositions disclosed herein.
A system includes an interface and a processor. The interface is configured to receive multiple electrophysiological (EP) signals from a tissue area along an ablation curve inside a cardiac chamber of a heart of a patient. The processor is configured to (i) generate local conduction vectors (LCVs) for the area based on the multiple EP signals, (ii) estimate a level of change between sets of LCVs along the ablation curve within the tissue area, and (iii) based on the level of change, identify a presence of a conduction gap in the ablation curve.
An apparatus includes a first jaw (16) and a second jaw (618, 718, 900) that cooperate to clamp and staple tissue (90). The second jaw includes a jaw body (620, 720, 902) and a distal tip (619, 719, 906) pivotable relative to the jaw body between a first discrete and a second discrete position. First and second openings (663, 784, 785, 932, 934) are both defined by one of the distal tip or a structure (621, 920) located proximal to the distal tip. A projection (637, 781, 918) is defined by the other of the distal tip or the structure. The projection is positionable within the first opening (663, 785, 932) to releasably retain the distal tip in the first discrete position, and within the second opening (663, 784, 934) to releasably retain the distal tip in the second discrete position.
In one exemplary mode, a phacoemulsification system includes a phacoemulsification probe, an irrigation tube to provide irrigation fluid into an eye, an irrigation pump to pump irrigation fluid into the eye, an aspiration tube convey aspiration fluid from the eye, an aspiration pump to pump the aspiration fluid from the eye, a sensor to provide a signal indicative of current intraocular pressure in the eye, and a pump controller to receive the signal provided by the sensor, compute a value of intraocular pressure at a future time responsively to the provided signal and an indicator of change in the intraocular pressure over time, and control the irrigation pump to adjust a flow rate of the irrigation fluid to maintain the intraocular pressure at a given intraocular pressure responsively to the computed value of the intraocular pressure at the future time.
A61L 27/42 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having an inorganic matrix
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
A system includes an interface and a processor. The interface is configured to receive multiple electrophysiological (EP) signals from a tissue area along an ablation curve inside a cardiac chamber of a heart of a patient. The processor is configured to (i) generate local conduction vectors (LCVs) for the area based on the multiple EP signals, (ii) estimate a level of change between sets of LCVs along the ablation curve within the tissue area, and (iii) based on the level of change, identify a presence of a conduction gap in the ablation curve.#
A method includes obtaining an electroanatomical map, which maps a portion of a heart while the heart experiences an arrhythmia, obtaining a sequence of images of the heart acquired by an ultrasonic probe, the sequence including one or more arrhythmic images acquired while the heart experiences the arrhythmia and one or more rhythmic images acquired while the heart is in sinus rhythm, the ultrasonic probe including a sensor that outputs, during the acquisition of the sequence of images, a signal indicating a location and an orientation of the probe in a coordinate system of the electroanatomical map, based on the signal, identifying, in one of the arrhythmic images, an anatomical portion represented by a particular portion of the electroanatomical map, by tracking the anatomical portion through the sequence of images, identifying the anatomical portion in at least one of the rhythmic images, and displaying an output in response thereto.
An apparatus includes a first jaw (16) and a second jaw (618, 718, 900) that cooperate to clamp and staple tissue (90). The second jaw includes a jaw body (620, 720, 902) and a distal tip (619, 719, 906) pivotable relative to the jaw body between a first discrete and a second discrete position. First and second openings (663, 784, 785, 932, 934) are both defined by one of the distal tip or a structure (621, 920) located proximal to the distal tip. A projection (637, 781, 918) is defined by the other of the distal tip or the structure. The projection is positionable within the first opening (663, 785, 932) to releasably retain the distal tip in the first discrete position, and within the second opening (663, 784, 934) to releasably retain the distal tip in the second discrete position.
A data propagation reporting system may obtain an annotation associated with health data associated with a patient and may determine, based on the annotation, utilization information associated with the patient's health data. The data propagation reporting system may generate a patient data utilization report that may include at least a portion of the utilization information associated with the patient. The utilization information may indicate at least one of: the system(s) in which the health data associated with the patient has been used, when the health data associated with the patient has been accessed, or the purpose(s) for which the health data associated with the patient has been used. The utilization information may indicate the control program(s) (e.g., system algorithms) to which the patient's data has been contributed. The utilization information may indicate the data collection(s) in which the patient's data has been included.
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
A surgical data management system may enable a patient to provide conditional consent(s). The patient granted consent may be associated with one or more condition(s), stipulation(s), and/or limitations of the scope, duration, and/or usage of their health data. The surgical data management system may be configured to check that patient data is only being used in accordance with the consent data (e.g., for the agreed upon purpose(s) and for the agreed upon time). In response to a data request for health data associated with a patient, the system may obtain a conditional consent associated with the patient. The system may determine whether to block access to at least a portion of the health data associated with the patient based on the data request and whether the condition(s) associated with the conditional consent have been met.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
42.
REDUCING INTRAOCULAR PRESSURE (IOP) FLUCTUATIONS DURING PHACOEMULSIFICATION
A phacoemulsification method includes specifying a target intraocular pressure (IOP) level to be maintained in an eye of a patient during a phacoemulsification procedure. A phacoemulsification probe is inserted into the eye. The eye is irrigated with irrigation fluid and material is aspired from the eye while aiming to maintain the target IOP level, including controlling IOP fluctuations by (i) when an actual IOP in the eye is in a defined high range, limiting the IOP fluctuations to a given value, and (ii) when the actual IOP is in a defined low range that is lower than the high range, allowing the IOP fluctuations to exceed the given value.
The present invention relates to stabilized pre-fusion human parainfluenza virus 3 (HPIV3) F protein, and fragments thereof. The invention also relates to nucleic acid molecules encoding such proteins and fragments, and to the use of the proteins, fragments and nucleic acid molecules.
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND (Ireland)
Inventor
Stamatas, Georgios N.
Sato, Takahiro
Oddos, Thierry
Hourihane, Jonathan
Irvine, Alan D.
Insel, Richard A.
Abstract
A method to predict a propensity of an infant to develop atopic dermatitis. The method includes observing the expression of S100A8/A9 on a skin area of an infant; comparing the expression to determined standard, wherein the determined standard is ascertained by measuring a level of the biomarker in a subject or pool of subjects who have demonstrated an absence of atopic dermatitis; and determining the propensity of an infant to develop atopic dermatitis, wherein an increase in the expression as compared to the determined standard indicates propensity of the infant to develop atopic dermatitis.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
45.
REDUCING INTRAOCULAR PRESSURE (IOP) FLUCTUATIONS DURING PHACOEMULSIFICATION
A phacoemulsification method includes specifying a target intraocular pressure (IOP) level to be maintained in an eye of a patient during a phacoemulsification procedure. A phacoemulsification probe is inserted into the eye. The eye is irrigated with irrigation fluid and material is aspired from the eye while aiming to maintain the target IOP level, including controlling IOP fluctuations by (i) when an actual IOP in the eye is in a defined high range, limiting the IOP fluctuations to a given value, and (ii) when the actual IOP is in a defined low range that is lower than the high range, allowing the IOP fluctuations to exceed the given value.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
48.
Display screen or portion thereof with computer icon
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
The present invention is related to compounds of formula (I) and compounds of formula (II) and pharmaceutical composition thereof, useful as agonists of the CB1 and/or CB2 receptor(s).
Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
58.
DEVICES AND METHODS FOR MINIMIZING DAMAGE TO SOFT TISSUE DURING A SURGICAL PROCEDURE
Devices and methods for improved access to a surgical site are the basis of the present disclosure. The improved access can be provided by way of a displacement wrap that can be used to engage tissue that impedes access to the surgical site. The displacement wrap, which can be a textile, can be wrapped around the tissue and subsequently manipulated to move the wrap, and thus the tissue, out of the way to improve access. The displacement wrap includes locking features formed in it that allow for selective tensioning of the tissue being engaged and moved. The locking features can engage another portion of the wrap and/or can be engaged by another component associated with the wrap, such as a locking suture. Methods of using the wrap in various surgical procedures that would benefit from moving tissue to improve surgical site access are also provided.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
TPLO plate includes a body and first and second distal holes. The body extends longitudinally from a proximal end to a distal end and defined via a first surface which, in an operative configuration, faces away from a bone and a second surface which, in the operative configuration, faces toward the bone. The body includes a proximal portion configured to be positioned over a cut and repositioned proximal segment of a tibia during a procedure and a distal portion extending along a longitudinal axis and configured to be positioned over a distal segment of the tibia during the procedure. The first hole extends through a proximal end of the distal portion of the body from the first surface to the second surface. The first hole includes an elongated portion and an offset portion open to and in communication with one another. The elongated portion extends along the longitudinal axis and an offset portion extending distally from the elongated portion along an offset axis, which extends at an angle relative to the longitudinal axis. The second hole extends through the distal portion of the body distally of the first hole from the first surface to the second surface. The second hole extends along the longitudinal axis in alignment with the elongated portion of the first hole and including a sloped compression surface along a distal portion thereof. The first hole is configured such that when a first distal compression to the osteotomy cut is applied via insertion of a bone fixation element into a distal portion of the second hole. The element translates along the offset axis from a central axis to a point of intersection to provide a cranial compression to the osteotomy cut.
A surgical instrument and related method includes an instrument body, a guide shaft distally projecting from the instrument body, and a first surgical tool. The guide shaft has a guide sidewall, a guide lumen, and a clearance opening radially extending through the guide sidewall in communication with the guide lumen. The first surgical tool has an elongate body and a distal head configured to deflect relative to the elongate body from a first position to a second position. The distal head in the first position is positioned within the guide lumen along the central axis. The distal head in the second position is deflected from the central axis and extends at least partially through the clearance opening thereby vacating at least a portion of the guide lumen for introducing a second surgical tool through the guide lumen.
A61B 17/24 - Surgical instruments, devices or methods, e.g. tourniquets for use in the oral cavity, larynx, bronchial passages or nose; Tongue scrapers
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 1/015 - Control of fluid supply or evacuation
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements
A system includes an interface and a processor. The interface is configured to receive a lesion parameter indicative of a specification of a lesion intended to be formed in tissue of an organ using at least one of first and second ablation modes intended to be applied sequentially to multiple sections of the tissue. The processor is configured to (i) select, for the first and second ablation modes, first and second sets of parameters, respectively, that when applied to the tissue, form the lesion having the lesion parameter, (ii) detect, for a section selected among the multiple sections, whether the first or second ablation mode has been selected, and (iii) control a catheter having at least an ablation electrode, to apply to the section ablation signals that are based on the selected ablation mode and are corresponding to the first or second ablation modes.
Disclosed is a surgical instrument for treating tissue in a surgical procedure. The surgical instrument comprises an end effector, comprising an anvil, and a staple cartridge. The surgical instrument further comprises a drive train operably coupled to the end effector, a motor configured to motivate the drive train based on a default control algorithm to affect a tissue treatment motion of the end effector, and a sensor configured to monitor an independent parameter of the surgical procedure. The independent parameter is independent of the motion of the end effector. The surgical instrument further comprises a control circuit coupled to the motor and the sensor. The control circuit is configured to receive an input from the sensor indicative of the independent parameter, and adjust the default control algorithm based on the independent parameter.
A surgical stapling system includes a motor, a gear reducer assembly, a drive train, and a motor controller. A method of controlling the motor includes applying a first signal to the motor, receiving drive train operational data, comparing the drive train data to baseline data, and applying a signal having a different shape than the first signal to the motor. A method of characterizing the motor includes transmitting a perturbation signal, receiving motor function parameters, determining stapler system characteristics, and adjusting a controller function. A method of controlling a stepper motor includes applying a signal to the stepper motor, receiving stepper motor operational data, comparing the data to baseline data, and adjusting the signal. Another method of controlling the motor includes receiving motor rotational data, receiving gear rotation data, calculating a mechanical transfer function, determining non-idealities of the stapling system, and modifying a control signal based on the non-idealities.
Disclosed is a surgical system for use with a surgical device. The surgical system comprises a remote processing device comprising a device control circuit and a surgical hub configured to communicably couple to the remote processing device and the surgical device. The surgical hub comprises a hub control circuit, wherein the hub control circuit and the device control circuit perform distributed processing. The surgical hub control circuit is configured to transmit a synchronization feature to the remote processing device, transmit a first subset of data associated with the surgical device to the remote processing device, perform a second analysis on a second subset of the data, determine a second result based on the second analysis, receive a first result from the remote processing device and synchronization data of the first result, assess a synchronicity of the first result and the second result based on the synchronization data.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
66.
SURGICAL SYSTEM WITH MOTOR RELATIVE CAPACITY INTERROGATIONS
A surgical instrument system comprising a drive train and a control circuit is disclosed. The drive train comprises a motor and a shaft actuatable by the motor to actuate a function of an end effector. The control circuit is coupled to the motor, wherein the control circuit is configured to determine a relative excess capacity of the drive train, compare the relative excess capacity to a predetermined shifting threshold, and increase the speed of the motor based on the relative excess capacity exceeding the predetermined shifting threshold.
A surgical instrument system comprising a motor system and a control circuit is disclosed. The motor system comprises a motor and a drive train movable by the motor to actuate a firing member through a staple firing stroke. The control circuit is coupled to the motor, wherein, during the staple firing stroke, the control circuit is configured to perform a first sensory action to determine if a speed of the motor can be increased to a first target speed, monitor a result of the first sensory action, adjust a parameter of a subsequent sensory action based on the monitored result of the first sensory action, and perform the subsequent sensory action with the adjusted parameter.
A surgical instrument is disclosed including an end effector, a firing member movable from an unfired position toward a fired position during a firing stroke, a firing system comprising a motor, and a control system. The end effector comprises a first jaw, a second jaw moveable relative to the first jaw, and a staple cartridge. The firing system is configured to drive the firing member through the firing stroke. The control system is configured to drive the firing member from the unfired position toward the fired position with the firing system, detect a force to fire the firing member toward the fired position, predict a future force to fire the firing member, based on the detected force to fire, and dynamically adjust a firing algorithm of the firing system, based on the prediction.
Patient health data and consent data may be managed. Conditional consent by a patient may be provided for utilizing their private health data in one or more of the following: the adaptation of procedures, instrument operation, system configuration, display of results and/or plans for device usage. The patient granted consent may be associated with one or more condition(s), stipulation(s), and/or limitations of the scope, duration, and/or usage of their health data. A health data management system may check that patient data is only being used in accordance with the consent data (e.g., for the agreed upon purpose(s) and for the agreed upon time).
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
A surgical data management system may adjust patient data access and display capabilities based on the location, the data origin, and/or the patient geographic characteristics associated with a patient data display interface. The patient data display interface may be located within or outside of the privacy protection boundary. The system may identify a region of the patient or a controlling jurisdiction of the patient's data usage. The system may determine a region-based consent requirement associated with the dataset based on the relevant controlling region and may determine whether to display the dataset via the patient data display interface based on the determined region-based consent requirement and patient consent data. The system may generate the patient data display interface based on the determining. The system may determine a regional law's bearing on patient consent and may adapt consent management accordingly.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
A consent management system may receive a request to modify consent data associated with a patient. The system may obtain patient capacity information associated with the patient and may determine whether to allow the patient to modify the consent data based on the obtained patient capacity information. The patient capacity information may indicate patient cognitive capacity, patient emotional capacity and/or the like. A response to the consent modification request may be generated based on the determining. For example, based on a determination that the obtained patient capacity information indicates that patient lacks the capacity to modify the consent data, the response may indicate a rejection of the request (e.g., may indicate that the consent data may not be modified). Based on a determination that the obtained patient capacity information indicates that patient possesses the capacity to modify the consent data, the response may indicate an approval of the request.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A health data management system may obtain a consent key for accessing health information associated with a patient. The system may determine that at least some of the health information associated with the patient is stored in an external system, different from the health data system. The external system may be, for example, a second health data management system or a secure storage container associated with the patient. The health data system may send a request to access the health information associated with the patient. The access request may include a consent key associated with the patient's consent data. The consent key may be, may include, and/or may indicate the patient's consent data. The health data system may access the health information associated with the patient from the external system (e.g., upon the external system authorizing access based on the consent key).
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
73.
Dosing Regimen for Therapies Comprising Bispecific Anti-EGFR/C-Met Antibodies
Provided are methods of treating an epidermal growth factor receptor (EGFR)-expressing or hepatocyte growth factor receptor (c-Met)-expressing cancer in a subject in need thereof. The methods comprise administering to the subject a therapy comprising an isolated bispecific anti-EGFR/c-Met antibody, wherein the administration comprises a dose of about 1400-2100 mg, administered once per a 21-day cycle.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A tool that enables professional-level monitoring at home can provide patients with better access to expert advice regarding skin care. The tool may enable providing information about skin health to a patient's skin care specialist such that the most relevant information is emphasized and presented in a manner expected. The device may include a processor configured to receive a first skin image at a first time and a second skin image at a second time. The first and second time may be separated by a duration associated with a skin event. A plurality of skin characteristics may be determined from the first skin image and the second skin image. The processor may be configured to generate an analysis output and to transmit the analysis output to one or more receivers. The analysis output may include a synoptic representation of one or more of the plurality of skin characteristics.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
In one exemplary mode, a phacoemulsification system includes a phacoemulsification probe, an irrigation tube to provide irrigation fluid into an eye, an irrigation pump to pump irrigation fluid into the eye, an aspiration tube convey aspiration fluid from the eye, an aspiration pump to pump the aspiration fluid from the eye, a sensor to provide a signal indicative of current intraocular pressure in the eye, and a pump controller to receive the signal provided by the sensor, compute a value of intraocular pressure at a future time responsively to the provided signal and an indicator of change in the intraocular pressure over time, and control the irrigation pump to adjust a flow rate of the irrigation fluid to maintain the intraocular pressure at a given intraocular pressure responsively to the computed value of the intraocular pressure at the future time.
A61M 1/00 - Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
76.
CONTACT LENS PACKAGE WITH DRAINING PORT AND METHOD OF ACCESSING A CONTACT LENS IN A CONTACT LENS PACKAGE
A contact lens package includes a base having a proximal end and a distal end, a solution well between the proximal end and the distal end, a contact lens support in the solution well, a top opening between the proximal end and the distal end and over the contact lens support, and a via through a wall of the base adjacent the well, the via providing a fluid exit for solution within well. A removable lid overlying the top opening may be removably affixed over the top opening such that a user may remove the lid to access the contact lens. Using this package, fluid can be drained away from the contact lens in the package before removal from the package by a user, thus providing good adhesion between a user's finger or applicator and the lens over prior packaging.
B65D 75/32 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
B65D 85/00 - Containers, packaging elements or packages, specially adapted for particular articles or materials
A45C 11/00 - Receptacles for purposes not provided for in groups
This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro-particles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of a pathogenic mycobacterial infection.
Disclosed is a surgical system, comprising an end effector configurable between an open state and a clamped state. The end effector comprises a first jaw and a second jaw moveable relative to the first jaw. The surgical system further comprises a drive system, comprising a motor and a drive assembly movable by the motor to effect a tissue-treatment motion at the end effector. The surgical system further comprises a motor control system comprising motor control electronics. The motor control system is configured to transmit a motor drive signal that causes the motor to move the drive assembly to effect the tissue- treatment motion at the end effector and control the motor control electronics to modify the tissue-treatment motion independent of the motor drive signal.
A surgical instrument is disclosed including a motor-powered firing system comprising a firing motor, a motor-powered closure system comprising a closure motor, and a control system. The firing motor is configured to drive a firing member between an unfired position and a fired position. The closure motor is configured to transition an end effector between an open state and a clamped state. The control system is configured to set a first parameter of the motor- powered closure system, based on a received first input, drive the end effector toward the clamped state with the motor-powered closure system using the first parameter, monitor a second parameter associated with the end effector transitioning toward the clamped state, set a third parameter of the motor-powered firing system, based on a received second input and the monitored second parameter, and drive the firing member toward the fired position using the third parameter.
A61B 17/072 - Surgical staplers for applying a row of staples in a single action
A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/92 - Identification means for patients or instruments, e.g. tags coded with colour
80.
SURGICAL SYSTEMS WITH DYNAMIC FORCE TO FIRE ADJUSTMENTS
A surgical instrument comprising an end effector, a firing member movable from an unfired position toward a fired position during a firing stroke, a firing system comprising a motor, and a control system. The firing system is configured to drive the firing member through the firing stroke. The control system is configured to drive the firing member from the unfired position toward the fired position with the firing system, detect a force to fire the firing member toward the fired position, pause advancement of the firing member for a first amount of time, based on the detected force to fire, resume advancement of the firing member after the first amount of time, and pause advancement of the firing member for a second amount of time, wherein the second amount of time is based on the first amount of time.
A61B 17/072 - Surgical staplers for applying a row of staples in a single action
A61B 17/00 - Surgical instruments, devices or methods, e.g. tourniquets
A61B 90/92 - Identification means for patients or instruments, e.g. tags coded with colour
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
81.
SURGICAL ALGORITHMS WITH INCREMENTAL SENSORY ACTIONS
A surgical instrument system comprising a motor system and a control circuit is disclosed. The motor system comprises a motor and a drive train movable by the motor to actuate a firing member through a staple firing stroke. The control circuit is coupled to the motor, wherein, during the staple firing stroke, the control circuit is configured to perform a first sensory action to determine if a speed of the motor can be increased to a first target speed, monitor a result of the first sensory action, adjust a parameter of a subsequent sensory action based on the monitored result of the first sensory action, and perform the subsequent sensory action with the adjusted parameter.
A61B 17/072 - Surgical staplers for applying a row of staples in a single action
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
82.
SURGICAL SYSTEMS WITH SYNCHRONIZED DISTRIBUTED PROCESSING CAPABILITIES
Disclosed is a surgical system for use with a surgical device. The surgical system comprises a remote processing device comprising a device control circuit and a surgical hub configured to communicably couple to the remote processing device and the surgical device. The surgical hub comprises a hub control circuit, wherein the hub control circuit and the device control circuit perform distributed processing. The surgical hub control circuit is configured to transmit a synchronization feature to the remote processing device, transmit a first subset of data associated with the surgical device to the remote processing device, perform a second analysis on a second subset of the data, determine a second result based on the second analysis, receive a first result from the remote processing device and synchronization data of the first result, assess a synchronicity of the first result and the second result based on the synchronization data.
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
A surgical instrument system comprising a motor system and a control circuit is disclosed. The motor system comprises a motor and a drive train coupleable to the motor and configured to actuate a firing member through a staple firing stroke. The control circuit is coupled to the motor, wherein the control circuit comprises a motor controller configured to control the motor, and wherein, during the staple firing stroke, the control circuit is configured to actuate the firing member through the staple firing stroke, monitor a parameter of the motor system during the staple firing stroke, identify when the firing member is within an active adjustment portion of the staple firing stroke; and automatically adjust, at a frequency, tuning parameters of the motor controller with based on the monitored parameter of the motor system during the active adjustment portion of the staple firing stroke.
Systems and methods for processing health data are provided. A health data processing system may comprise a processor configured to: obtain a dataset comprising health data; obtain an indication of a control program for a medical device; determine, for the control program, a utilization score of the dataset comprising the health data; and associate the utilization score with the health data. A health data processing system may comprise a processor configured to: detect a change in a consent associated with a patient; identify personal data associated with the change in the consent; identify a trained machine learning (ML) model to which the personal data has contributed; determine input data which has been used to train the trained ML model, wherein the input data comprises the personal data; determine, based on the change in the consent associated with the personal data, whether to replace the personal data in the input data with replacement data or to remove the personal data from the trained ML model; and adjust the input data or adjust the trained ML model based on the determination of whether to replace the personal data in the input data with the replacement data or to remove the personal data from the trained ML model. A data propagation reporting system may comprise a processor configured to: obtain an annotation associated with health data associated with a patient; determine, based on the annotation, utilization information associated with the health data; and generate a patient data utilization report comprising at least a portion of the utilization information associated with the patient. A health data system comprising: a processor configured to: determine that health information associated with a patient is stored in an external system, the external system being different from the health data system; obtain a consent key for accessing the health information associated with the patient; send a request to access the health information associated with the patient, wherein the request comprises the consent key; and access the health information from the external system.
G06F 16/215 - Improving data quality; Data cleansing, e.g. de-duplication, removing invalid entries or correcting typographical errors
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
85.
POWER ASSIST FOR A MANUAL AND AUTOINJECTOR INJECTION DEVICE
A power-assisted injection device can administer a liquid medication. The injection device can include a syringe, a housing, and a motive force device. The syringe can include a plunger and a barrel configured for holding the liquid medication. The housing can include a body configured for holding the syringe. The housing can also include a latch configured to define a locked position that inhibits movement of the plunger and a released position that enables movement of the plunger. The motive force device can be configured for applying an injection force to the plunger to administer the medication while the latch is in the released position. The injection device can be configured for administering the liquid medication upon release of the latch from the locked position at least in part via the motive force device applying the injection force to the plunger of the syringe.
A61M 5/32 - Syringes - Details - Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
A tool that enables professional-level monitoring at home can provide patients with better access to expert advice regarding skin care. The tool may enable providing information about skin health to a patient's skin care specialist such that the most relevant information is emphasized and presented in a manner expected. The device may include a processor configured to receive a first skin image at a first time and a second skin image at a second time. The first and second time may be separated by a duration associated with a skin event. A plurality of skin characteristics may be determined from the first skin image and the second skin image. The processor may be configured to generate an analysis output and to transmit the analysis output to one or more receivers. The analysis output may include a synoptic representation of one or more of the plurality of skin characteristics.
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Described are gummy dosage forms comprising tricalcium phosphate and a relaxing ingredient selected from Lemon balm extract, L-theanine, GABA, or mixtures thereof.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
88.
TRICYCLIC PYRIMIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS
The invention relates to pharmaceutical compounds of formula (I) and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of cyclin-dependent kinase 7 (CDK7) and to their use in the treatment of diseases, e.g., cancer.
The invention relates to pharmaceutical compounds of formula (I) and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of cyclin-dependent kinase 7 (CDK7) and to their use in the treatment of diseases, e.g., cancer.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2, R3 and R4 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2, R3 and R4 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
An occlusive device can include a braided segment including an open end, a pinched end, and an embolic coil. The tubular braid can include a band positioned approximate the pinched end which can attach the embolic coil to the braided segment. In a deployed configuration, the embolic coil can extend in a distal direction from the band and form a looped shape within an approximately spherical cavity, and the braided segment can extend from the band in a distal direction and include two inversion forming three sections which at least partially overlap each other, with the pinched end affixed to an innermost section, the band affixed to the innermost section, and a middle section between the two inversion positioned within an outermost section and around the innermost section.
A61B 17/12 - Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
91.
ULTRASONIC SURGICAL INSTRUMENT WITH TRANSDUCER SLIP JOINT
A surgical instrument for use during a surgical procedure includes an instrument body, an ultrasonic transducer assembly extending along a longitudinal axis, a power cord, and a transducer slip joint. The ultrasonic transducer assembly is rotatably mounted within the instrument body about the longitudinal axis and defines a first outer profile. The power cord projects from the instrument body to provide electrical power to the ultrasonic transducer assembly for operating an acoustic waveguide. The transducer slip joint is positioned between the power cord and the ultrasonic transducer assembly and electrically and mechanically connects the power cord to the ultrasonic transducer assembly. The ultrasonic transducer assembly selectively rotates relative to the power cord for inhibiting the power cord from winding upon rotation of the ultrasonic transducer assembly. The transducer slip joint also defines a second outer profile that fits within the first outer profile of the ultrasonic transducer assembly.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A method of operating an articulatable surgical instrument. The method includes providing a rotary drive motion to a rotary drive member of a surgical end effector and converting the rotary drive motion to an upper axial motion and a lower axial motion at locations that are distal to the articulation joint. The method further includes applying the upper axial motion to an upper portion of a firing member and applying the lower axial motion to a lower portion of the firing member such that the upper axial motion and lower axial motion drives the firing member distally through the surgical end effector from a starting position to an ending position.
A method of operating a surgical instrument is disclosed. The surgical instrument includes an electronic system comprising an electric motor coupled to the end effector; a motor controller coupled to the motor; a parameter threshold detection module configured to monitor multiple parameter thresholds; a sensing module configured to sense tissue compression; a processor coupled to the parameter threshold detection module and the motor controller; and a memory coupled to the processor. The memory stores executable instructions that when executed by the processor cause the processor to monitor multiple levels of action thresholds and monitor speed of the motor and increment a drive unit of the motor, sense tissue compression, and provide rate and control feedback to the user of the surgical instrument.
An apparatus including a body, a shaft assembly extending distally from the body, and an end effector configured to grasp and transmit RF energy to the tissue. The end effector includes a first jaw having a first tissue grasping feature and a second jaw. The second jaw is pivotably coupled to the first jaw between an open position, a partially closed position, and a closed position. The second jaw includes a proximal taper having a proximal electrode surface, a distal taper including a distal electrode surface, and a juncture between the proximal and distal electrode surface. The juncture is spaced further from the first tissue grasping feature compared to the proximal and distal end while the second jaw is in the partially closed position. The proximal and distal electrode surface deform to define a gap with the first tissue grasping feature while in the closed position.
A robotic surgical tool includes a tool driver including a first inductive coil, a drive housing releasably mounted to the tool driver and including a second inductive coil, a shaft extending from the drive housing and terminating at an end effector operatively coupled to a distal end of the shaft, and a firing rod extending from the drive housing within the shaft and terminating at the end effector, the firing rod including a magnetically responsive material and being movable within the drive housing between a retracted position and an extended position. One of the inductive coils generates a magnetic field, and the other measures an intensity of the magnetic field and a field distortion caused by movement of the firing rod. A change in the field distortion provides an indication of movement of the firing rod between the retracted and extended positions.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 17/072 - Surgical staplers for applying a row of staples in a single action
A61B 34/00 - Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
Surgical tools that are capable of a higher mechanical advantage without increasing the overall width of the tool. The surgical tool includes a wrist that may comprise a first pulley adjacent to a second pulley, the first pulley may have a first lip and a second lip, and the second pulley may have a first lip and second lip. The first lip of the second pulley overlaps the second lip of the first pulley and at least a portion of the first lip of the second pulley is recessed within a body of the first pulley.
A surgical instrument is disclosed including an end effector configurable between an open state and a clamped state, a firing member movable from an unfired position toward a fired position during a firing stroke, a manually-driveable closure system, a motor-powered firing system, and a control system. The motor-powered firing system is configured to drive the firing member through the firing stroke. The control system is configured to detect, at a first time point, the end effector reaching the clamped state with the manually-driveable closure system, detect, at a second time point, the actuation of the motor-powered firing system, set a firing motion parameter of the motor-powered firing system based on an elapsed time from the first time point to the second time point, and drive the firing member through the firing stroke with the motor-powered firing system using the firing motion parameter.
A surgical instrument is disclosed including a motor-powered firing system comprising a firing motor, a motor-powered closure system comprising a closure motor, and a control system. The firing motor is configured to drive a firing member between an unfired position and a fired position. The closure motor is configured to transition an end effector between an open state and a clamped state. The control system is configured to set a first parameter of the motor-powered closure system, based on a received first input, drive the end effector toward the clamped state with the motor-powered closure system using the first parameter, monitor a second parameter associated with the end effector transitioning toward the clamped state, set a third parameter of the motor-powered firing system, based on a received second input and the monitored second parameter, and drive the firing member toward the fired position using the third parameter.
A surgical system is disclosed including a surgical instrument and a control system. The surgical instrument comprises an end effector, a first drive system, and a second drive system. The control system is configured to detect the actuation of the first drive system of the surgical instrument, drive a first function of the end effector using the first drive system, monitor a first parameter associated with a first function, set a second parameter associated with a second function of the end effector based on the monitored first parameter, and drive the second function of the end effector using the second drive system.
A surgical stapling system includes an anvil, a blade, a motor and gear assembly, a motor power supply, and a motor controller. A method of controlling the motor includes receiving first and second data indicative of operations of the motor under first and second conditions, respectively, and adjusting a motor control signal based on a difference between the first and second data. Another method includes receiving initial manufacture motor and gear assembly data from a manufacture and operational data during an initial use of the system, and adjusting parameters of the control signal based on a difference between the manufacture data and the operational data. Another method includes controlling a pulse-width modulated (PWM) motor control signal, receiving data regarding an interaction between the blade and a tissue clamped by the anvil, and adjusting a frequency of the PWM signal based on the data related to the interaction.
